12h
Alkermes outlines $1.73B–$1.84B 2026 revenue target as Avadel acquisition expands commercial reach
Q4 2025 earnings call recap: 2026 revenue/EBITDA guidance, Avadel-LUMRYZ integration, pipeline catalysts, and key risks—read now.
Ooops... Something went wrong while loading this page.
Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations. Incubated by Flagship Pioneering, Generate applies AI ...
For over 5 years, Arthur has been professionally covering video games, writing guides and walkthroughs. His passion for video games began at age 10 in 2010 when he first played Gothic, an immersive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results